Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases
Mechanisms of Ageing and Development · 2024-12 · 222 · 111995
DOI: 10.1016/j.mad.2024.111995 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mechanisms of Ageing and Development, 2024-12. Verfasst von Juliette Tavenier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Kettegaard Allé 30, Hvidovre 2650, Denmark. Electronic address: …. Hauptthemen laut MEDLINE: Flavonols, Flavonoids, Senotherapeutics, Cellular Senescence. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Hartmann Foundation, Capital Region of Denmark.
Abstract (Originalsprache)
Fisetin, a flavonoid naturally occurring in plants, fruits, and vegetables, has recently gained attention for its potential role as a senotherapeutic agent for the treatment of age-related chronic diseases. Senotherapeutics target senescent cells, which accumulate with age and disease, in both circulating immune cell populations and solid organs and tissues. Senescent cells contribute to development of many chronic diseases, primarily by eliciting systemic chronic inflammation through their senescence-associated secretory phenotype. Here, we explore whether fisetin as a senotherapeutic can eliminate senescent cells, and thereby alleviate chronic diseases, by examining current evidence from in vitro studies and animal models that investigate fisetin's impact on age-related diseases, as well as from phase I/II trials in various patient populations. We discuss the application of fisetin in humans, including challenges and future directions. Our review of available data suggests that targeting senescent cells with fisetin offers a promising strategy for managing multiple chronic diseases, potentially transforming future healthcare for older and multimorbid patients. However, further studies are needed to establish the safety, pharmacokinetics, and efficacy of fisetin as a senotherapeutic, identify relevant and reliable outcome measures in human trials, optimize dosing, and better understand the possible limitations of fisetin as a senotherapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Kettegaard Allé 30, Hvidovre 2650, Denmark. Electronic address: juliette.tavenier@regionh.dk.
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Kettegaard Allé 30, Hvidovre 2650, Denmark. Electronic address: jan.nehlin@regionh.dk.
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Kettegaard Allé 30, Hvidovre 2650, Denmark; The Hospital Pharmacy, Marielundsvej 25, Herlev 2730, Denmark; Department of Drug Design a…
- Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen 2200, Denmark. Electronic address: lenera@sund.ku.dk.
- Center for Advanced Gerotherapeutics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Division of General Internal Medicine, C…
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Kettegaard Allé 30, Hvidovre 2650, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Cop…
Förderung
- NIA NIH HHS
- Hartmann Foundation
- Capital Region of Denmark
- Copenhagen University Hospital Hvidovre
- Beckett Foundation
- National Institutes of Health
- Noaber Foundation
Zitieren
APA
Tavenier, J., Nehlin, J. O., Houlind, M. B., Rasmussen, L. J., Tchkonia, T., Kirkland, J. L., Andersen, O., & Rasmussen, L. J. H. (2024). Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mechanisms of Ageing and Development, 222, 111995. https://doi.org/10.1016/j.mad.2024.111995
Vancouver
Tavenier J, Nehlin JO, Houlind MB, Rasmussen LJ, Tchkonia T, Kirkland JL, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mechanisms of Ageing and Development. 2024;222:111995. doi:10.1016/j.mad.2024.111995
BibTeX
@article{Tavenier2024,
author = {Tavenier, Juliette and Nehlin, Jan O and Houlind, Morten Baltzer and Rasmussen, Lene Juel and Tchkonia, Tamara and Kirkland, James L and Andersen, Ove and Rasmussen, Line Jee Hartmann},
title = {Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases},
journal = {Mechanisms of Ageing and Development},
year = {2024},
volume = {222},
pages = {111995},
doi = {10.1016/j.mad.2024.111995}
}
EUVIMED